Revvity Is Maintained at Outperform by Raymond James
Revvity Analyst Ratings
Raymond James Maintains Revvity(RVTY.US) With Buy Rating, Cuts Target Price to $140
Bernstein Maintains Revvity(RVTY.US) With Hold Rating, Maintains Target Price $130
Analysts Offer Insights on Healthcare Companies: Teleflex (TFX) and Revvity (RVTY)
Bernstein Maintains Revvity(RVTY.US) With Hold Rating, Announces Target Price $130
Revvity's Strong Financial Performance and Favorable Portfolio Support Buy Rating Despite Market Challenges
Bernstein Maintains Revvity(RVTY.US) With Hold Rating
BofA Securities Maintains Revvity(RVTY.US) With Buy Rating, Maintains Target Price $138
TD Cowen Maintains Revvity(RVTY.US) With Buy Rating, Maintains Target Price $144
Stifel Maintains Revvity(RVTY.US) With Hold Rating, Maintains Target Price $120
Stifel Nicolaus Reaffirms Their Hold Rating on Revvity (RVTY)
TD Cowen Reaffirms Their Buy Rating on Revvity (RVTY)
BofA Securities Maintains Revvity(RVTY.US) With Buy Rating, Maintains Target Price $138
Revvity Receives Buy Rating for Strong Q4 Performance and Attractive Valuation
Bernstein Downgrades Revvity(RVTY.US) to Hold Rating, Cuts Target Price to $130
Bernstein Maintains Revvity(RVTY.US) With Buy Rating, Maintains Target Price $145
Bernstein Remains a Buy on Revvity (RVTY)
Evercore Maintains Revvity(RVTY.US) With Buy Rating, Cuts Target Price to $125
Citi Maintains Revvity(RVTY.US) With Buy Rating, Maintains Target Price $145